HSF1-Activating Compounds for Protein Misfolding Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for protein misfolding diseases such as Alzheimer's and Parkinson's lack effective methods to address protein misfolding and aggregation, leading to inadequate clearance and function, which are critical for neuronal health and overall cellular well-being.
Innovation Solution
Development of compounds capable of activating the human Heat Shock Transcription Factor 1 (HSF1), specifically through high-throughput screening, to facilitate HSF1 activation, promoting protein folding, solubilization, and degradation, thereby improving intracellular quality control and treating conditions associated with protein misfolding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for protein misfolding diseases, then existing therapeutic approaches are maintained, but effective clearance of misfolded proteins is inadequate
Solution Approach 1:
The patent changes the biochemical parameters of the cell by introducing small molecule compounds that activate HSF1, thereby altering the cellular response to protein misfolding and enhancing the clearance mechanism through heat shock protein upregulation
Solution Approach 2:
The patent uses HSF1 as an intermediary mediator that, when activated by small molecule compounds, triggers the expression of heat shock proteins which then facilitate the clearance of misfolded proteins, creating an indirect but effective treatment pathway
2Reliability
If no effective HSF1 activation method is used, then existing therapeutic limitations persist, but protein folding and clearance functions remain insufficient
Solution Approach 1:
The patent enables the cell's own quality control mechanisms to be activated by small molecule compounds that trigger HSF1, allowing the cellular system to self-correct protein misfolding issues through endogenous heat shock protein production rather than requiring complex external intervention systems
Data Source
AI summary
The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.